Cancer, inflammation, and therapy: effects on cytochrome p450-mediated drug metabolism and implications for novel immunotherapeutic agents. (Q38225574)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24987833%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

title

Cancer, inflammation, and therapy: effects on cytochrome p450-mediated drug metabolism and implications for novel immunotherapeutic agents (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24987833%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24987833%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

author name string

R Donald Harvey

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24987833%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

language of work or name

English

0 references

publication date

2 July 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24987833%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

21 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24987833%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

volume

96

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24987833%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24987833%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

page(s)

449-457

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24987833%20AND%20SRC:MED&resulttype=core&format=json

Monocytes and macrophages regulate immunity through dynamic networks of survival and cell death

21 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Innate immunity: the virtues of a nonclonal system of recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Intracellular toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Identification and functions of pattern-recognition receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Pattern recognition receptors and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

How are T(H)2-type immune responses initiated and amplified?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Immunity, Inflammation, and Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the U.S.A.: 2005-09.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

The growing challenge of obesity and cancer: an inflammatory issue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Inflammation and cancer: back to Virchow?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Immune surveillance of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Analgesic and anti-inflammatory drug use and risk of bladder cancer: a population based case control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fiber for colorectal cancer chemoprevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Activation of the acute inflammatory response alters cytochrome P450 expression and eicosanoid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Cytochrome P450-derived eicosanoids: the neglected pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Critical review of preclinical approaches to investigate cytochrome p450-mediated therapeutic protein drug-drug interactions and recommendations for best practices: a white paper

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Regulation of drug-metabolizing enzymes and transporters in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Extra-hepatic cancer represses hepatic drug metabolism via interleukin (IL)-6 signalling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Modulation of hepatic cytochrome P450s by Citrobacter rodentium infection in interleukin-6- and interferon-{gamma}-null mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

The effect of infliximab on hepatic cytochrome P450 and pharmacokinetics of verapamil in rats with pre-adjuvant arthritis: a drug-disease and drug-drug interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

An update on drug-drug interactions with biologics for the treatment of moderate-to-severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Interleukins-12 and -23 do not alter expression or activity of multiple cytochrome P450 enzymes in cryopreserved human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Spontaneous regression of melanoma may offer insight into cancer immunology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Factors affecting cytochrome P-450 3A activity in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Principles of cancer therapy: oncogene and non-oncogene addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Cutting edge: IL-12 and type I IFN differentially program CD8 T cells for programmed death 1 re-expression levels and tumor control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Signaling through OX40 enhances antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Immunologic and clinical effects of targeting PD-1 in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Hepatotoxicity with combination of vemurafenib and ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Quantification of cortisol and 6 beta-hydroxycortisol in human urine by LC-MS/MS, and gender-specific evaluation of the metabolic ratio as biomarker of CYP3A activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Hepatic cytochrome P450 down-regulation during aseptic inflammation in the mouse is interleukin 6 dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

Analgesic therapy and the prevention of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

7 January 2021

Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

7 January 2021

Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

7 January 2021

Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

7 January 2021

Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.143

7 January 2021

Identifiers

DOI

10.1038/CLPT.2014.143

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24987833%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

21 March 2020

1031126093

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24987833%20AND%20SRC:MED&resulttype=core&format=json